No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
EW Edwards Lifesciences
- 85.660
- -2.480-2.81%
Trading Jun 10 13:30 ET
51.62BMarket Cap36.92P/E (TTM)
87.860High85.600Low935.36KVolume87.740Open88.140Pre Close80.96MTurnover0.16%Turnover Ratio37.24P/E (Static)602.60MShares96.12052wk High7.25P/B51.10BFloat Cap60.57052wk Low--Dividend TTM596.58MShs Float131.730Historical High--Div YieldTTM2.56%Amplitude1.000Historical Low86.554Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Jefferies Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $102
Jefferies analyst Matthew Taylor maintains $Edwards Lifesciences(EW.US)$ with a buy rating, and maintains the target price at $102.According to TipRanks data, the analyst has a success rate of 60.3% a
Express News | NYSE Order Imbalance 63061.0 Shares on Sell Side
TD Cowen Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $100
TD Cowen analyst Josh Jennings maintains $Edwards Lifesciences(EW.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 52.4% and
Express News | NYSE Order Imbalance 65222.0 Shares on Sell Side
Edwards Lifesciences Presents 5-Year Follow Up Data From PARTNER Trials Showing Clinical Outcomes For Female And Small Annulus Patients With Transcatheter Aortic Valve Replacement At The New York Valves 2024: The Structural Heart Summit
Edwards Lifesciences (NYSE:EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small an
The Most Crowded Longs and Shorts in U.S. Med-Tech for May - UBS
Comments
Edwards Lifesciences' impressive ROCE history and its ability to generate high returns on increasing amounts of capital employed indicate strong fundamentals. This warrants further research into the stock despite it being more 'expensive' than before.
Edwards Lifesciences (NYSE:EW) Is Aiming To Keep Up Its Impressive ReturnsAnalysts reconfirmed revenue and earnings forecasts for Edwards Lifesciences, indicating no major change in business expectations following recent results. The price target increase suggests analysts believe the business's intrinsic value is improving.
Investors banking on Edwards Lifesciences' high P/E ratio might face a challenge as the firm's predicted market-aligned growth hints at a potential share price decline.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $Align Technology(ALGN.US$ - up 11.5%
2. $Textron(TXT.US$ - up 5.2%
3. $STMicroelectronics(STM.US$ - up 4.1%
4. $Lam Research(LRCX.US$ - up 3.9%
5. $RELX PLC(RELX.US$ - up 3.1%
6. $Royal Caribbean(RCL.US$ - up 3.1%
7. $Micron Technology(MU.US$ - up 3.1%
8. $Western Digital(WDC.US$ - up 2.9...
Gap Ups
1. $Align Technology(ALGN.US$ - up 11.5%
2. $Textron(TXT.US$ - up 5.2%
3. $STMicroelectronics(STM.US$ - up 4.1%
4. $Lam Research(LRCX.US$ - up 3.9%
5. $RELX PLC(RELX.US$ - up 3.1%
6. $Royal Caribbean(RCL.US$ - up 3.1%
7. $Micron Technology(MU.US$ - up 3.1%
8. $Western Digital(WDC.US$ - up 2.9...
+17
18
Pre-Market Stock Movers
Gapping up
$Align Technology(ALGN.US$
(The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.)
$Meta Platforms(META.US$
(The Facebook parent jumped ne...
Gapping up
$Align Technology(ALGN.US$
(The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.)
$Meta Platforms(META.US$
(The Facebook parent jumped ne...
17
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg